Literature DB >> 19415654

Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7.

Simon Staubach1, Hanieh Razawi, Franz-Georg Hanisch.   

Abstract

Apically expressed human MUC1 is known to become endocytosed and either to re-enter the secretory pathway for recycling to the plasma membrane or to be exported by the cells via the formation of multi-vesicular bodies and the release of exosomes. By using recombinant fusion-tagged MUC1 as a bait protein we followed an anti-myc affinity-based approach for isolating subpopulations of lipid rafts from the plasma membranes and exosomes of MCF-7 breast cancer cells. MUC1(+) lipid rafts were not only found to contain genuine raft proteins (flotillin-1, prohibitin, G protein, annexin A2), but also raft-associated proteins linking these to the cytoskeleton (ezrin/villin-2, profilin II, HSP27, gamma-actin, beta-actin) or proteins in complexes with raft proteins, including the bait protein (HSP60, HSP70). Major overlaps were revealed for the subproteomes of plasma membranous and exosomal lipid raft preparations, indicating that MUC1 is sorted into subpopulations of rafts for its trafficking via flotillin-dependent pathways and export via exosomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415654     DOI: 10.1002/pmic.200800793

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  75 in total

Review 1.  Annexins as organizers of cholesterol- and sphingomyelin-enriched membrane microdomains in Niemann-Pick type C disease.

Authors:  Magdalena Domon; Mehmet Nail Nasir; Gladys Matar; Slawomir Pikula; Françoise Besson; Joanna Bandorowicz-Pikula
Journal:  Cell Mol Life Sci       Date:  2011-12-13       Impact factor: 9.261

2.  The role of Lamin A in cytoskeleton organization in colorectal cancer cells: a proteomic investigation.

Authors:  Clare R Foster; Joanne L Robson; William J Simon; Jeremy Twigg; Derek Cruikshank; Robert G Wilson; Chris J Hutchison
Journal:  Nucleus       Date:  2011-09-01       Impact factor: 4.197

Review 3.  Microvesicles and viral infection.

Authors:  David G Meckes; Nancy Raab-Traub
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

4.  Lipid rafts association and anti-apoptotic function of prohibitin in ultraviolet B light-irradiated HaCaT keratinocytes.

Authors:  Qiong Wu; Shiyong Wu
Journal:  Exp Dermatol       Date:  2012-08       Impact factor: 3.960

5.  Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes.

Authors:  Elham Hosseini-Beheshti; Steven Pham; Hans Adomat; Na Li; Emma S Tomlinson Guns
Journal:  Mol Cell Proteomics       Date:  2012-06-21       Impact factor: 5.911

Review 6.  Extracellular vesicles in breast cancer drug resistance and their clinical application.

Authors:  Shentong Yu; Yifang Wei; Yuqiao Xu; Yuan Zhang; Jipeng Li; Jian Zhang
Journal:  Tumour Biol       Date:  2016-01-21

7.  Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions.

Authors:  Amos M Sakwe; Rainelli Koumangoye; Bobby Guillory; Josiah Ochieng
Journal:  Exp Cell Res       Date:  2010-12-24       Impact factor: 3.905

8.  Secretion modification region-derived peptide disrupts HIV-1 Nef's interaction with mortalin and blocks virus and Nef exosome release.

Authors:  Martin N Shelton; Ming-Bo Huang; Syed A Ali; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

9.  Astrocytes and Glioblastoma cells release exosomes carrying mtDNA.

Authors:  Michele Guescini; Susanna Genedani; Vilberto Stocchi; Luigi Francesco Agnati
Journal:  J Neural Transm (Vienna)       Date:  2009-08-13       Impact factor: 3.575

Review 10.  The potential of tumor-derived exosomes for noninvasive cancer monitoring.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2015-08-02       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.